Other
Treatment
0
Pipeline Programs↗
427
Active Trials↗
204
Companies Involved↗
Treatment is an early-stage landscape with 0 programs across 204 companies. The most active players are Novartis, GSK, Bayer.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
2,937
clinical trials
Completed1,663 · 57%
Unknown status442 · 15%
Terminated247 · 8%
Recruiting220 · 7%
Active, not recruiting119 · 4%
Withdrawn102 · 3%
Other144 · 5%
Clinical Trials
Trial Activity
2937 trials
Anlotinib Capsules in the Treatment for IPF/PF-ILDs
Recruiting·FFirst Affiliated Hospital of Wenzhou Medical University·Phase 2/3·NCT05828953·30 enrolled
Repurposing Nucleoside Reverse Transcriptase Inhibitors for Treatment of AD
Recruiting·—·Phase 1·NCT04500847·35 enrolled
Different Administration Regimens of CAZ-AVI in Combination With ATM for the Treatment of CR-GNB
Recruiting·—·Phase 4·NCT07478484·144 enrolled
Calcitonin Pre-treatment to Improve SPECT-CT Sensitivity
Recruiting·—·Phase 4·NCT03935984·37 enrolled
Page 1 of 196
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)